Developing Novel TRH-based Drug Treatment for Neurodegenerative Diseases
Neuropath Therapeutics, located in Dublin, Ireland, is a late preclinical stage biotech developing an innovative neurotherapeutic drug treatment based on thyrotropin-releasing hormone (TRH) – a naturally occurring neuropeptide, long recognized for its broad range of therapeutic actions that counteract multiple pathogenic processes key to the etiology of neurodegenerative diseases (NDs).
Our mission is to deliver first-in-class TRH-based therapeutics to mitigate cognitive and motor impairments and slow disease progression in patients with NDs and other conditions of compromised brain health.
This TRH-based strategy offers a distinct, multifactorial neurotherapeutic approach with major clinical and commercial potential across multiple indications, such as Alzheimer’s Disease, ALS/MND, and traumatic brain injury, among others.
Founded on discoveries at Trinity College Dublin (TCD), Neuropath’s new-generation TRH-based compounds incorporate a novel design that overcomes pharmacological limitations that historically have limited clinical exploitation of TRH.
Neuropath’s lead candidate has successfully completed comprehensive preclinical development with top-tier CROs, including an IND/CTA-enabling workup. This lead has been granted orphan drug designation for ALS by the FDA and EMA and is now positioned for first-in-human/Phase 1 clinical studies and early proof of principle.
Preclinical proof-of-concept studies demonstrate that this compound modulates relevant disease biology at molecular, cellular and functional levels; it is shown to significantly reduce glutamate-induced excitotoxicity and oxidative stress, protect neurons from cell death, and lessen cognitive and motor deficits.
